GNTLF (Genetic Technologies) 3-Year Revenue Growth Rate : 287.10% (As of Jun. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Genetic Technologies 3-Year Revenue Growth Rate?

Genetic Technologies's Revenue per Share for the three months ended in Jun. 2024 was $0.00.

During the past 12 months, Genetic Technologies's average Revenue per Share Growth Rate was -32.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 287.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Genetic Technologies was 319.80% per year. The lowest was -71.90% per year. And the median was -17.80% per year.

Competitive Comparison of Genetic Technologies's 3-Year Revenue Growth Rate

For the Diagnostics & Research subindustry, Genetic Technologies's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies's 3-Year Revenue Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's 3-Year Revenue Growth Rate falls into.

Genetic Technologies 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Genetic Technologies (OTCPK:GNTLF) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Genetic Technologies 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (OTCPK:GNTLF) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

GENE:USA 0A4N:UK DU8:Germany GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.